A5012509026- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Telomeres, Telomerase, and Senescence
- Histone Deacetylase Inhibitors Research
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer-related cognitive impairment studies
- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Cystic Fibrosis Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Pneumocystis jirovecii pneumonia detection and treatment
- Gastric Cancer Management and Outcomes
- Birth, Development, and Health
- Genetics, Aging, and Longevity in Model Organisms
- Dupuytren's Contracture and Treatments
- Drug-Induced Adverse Reactions
- Cancer therapeutics and mechanisms
- Advanced biosensing and bioanalysis techniques
- Mycobacterium research and diagnosis
The Ohio State University
2020-2025
The Ohio State University Wexner Medical Center
2016-2024
Ohio University
2024
Buck Institute for Research on Aging
2016-2021
Cellular senescence suppresses cancer by irreversibly arresting cell proliferation. Senescent cells acquire a proinflammatory senescence-associated secretory phenotype. Many genotoxic chemotherapies target proliferating nonspecifically, often with adverse reactions. In accord prior work, we show that several chemotherapeutic drugs induce of primary murine and human cells. Using transgenic mouse permits tracking eliminating senescent cells, therapy-induced (TIS) persist contribute to local...
Abstract Venetoclax has efficacy in patients relapsing after B-cell receptor pathway inhibitors (BCRis); however, because of the risk tumor lysis syndrome (TLS), a 5-week dose ramp-up is required to attain target dose. Patients BCRis frequently have proliferative disease, requiring faster time than this scheme allows. This limitation can potentially be overcome with rapid escalation (RDE). We analyzed 33 chronic lymphocytic leukemia who underwent venetoclax RDE prior BTKi treatment. Median...
Aging is characterized by systemic declines in tissue and organ functions. Interventions that slow these represent promising therapeutics to protect against age-related disease improve the quality of life. In this study, several interventions associated with lifespan extension invertebrates or improvement were tested mouse models determine if they effective slowing aging a broad spectrum functional assays. Benzoxazole, which extends Caenorhabditis elegans, slowed femoral bone loss mice....
Myelodysplastic syndromes (MDS) are typically a hematologic malignancy of older adults characterized by dysplastic hematopoiesis, cytopenia(s), and risk acute myeloid leukemia transformation. The treatment approach to MDS depends largely on stratification an individual's disease, most commonly using the Revised International Prognostic Scoring System, which takes into account peripheral blood cytopenias bone marrow blast percentage cytogenetics. current standard care for patients with...
Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for chronic myelomonocytic leukemia (CMML). While HMA decitabine, its intravenous formulation, has been used since 2006 CMML, use oral formulation limited by poor bioavailability due to first-pass metabolism enzyme cytidine deaminase. The dose decitabine is toxicities such as cardiomyopathy heart failure. Therefore, cedazuridine was developed an inhibitor Cedazuridine decreases...
Linear IgA bullous dermatosis (LABD) is a rare subepidermal-blistering disease caused by antibasement membrane antibodies. The exact pathogenesis of LABD remains unknown. In adults, typically antibiotics, such as vancomycin, penicillins, cephalosporins, and sulfonamides.1 Antihypertensives, antiepileptics, analgesics, immunosuppressive medications, cyclosporine, have also been implicated.2 first step in management withdrawal the causative agent. first-line therapeutic agent dapsone,...
Background: BCL-2 inhibition to target intrinsic apoptotic pathways that confer a survival advantage leukemic blasts has become key therapeutic strategy for patients (pts) with myeloid malignancies. LP-108 is an oral highly potent and selective inhibitor of comparable or more in vitro inhibitory activity compared the FDA approved venetoclax. Aims: We present safety preliminary efficacy data pts treated ongoing phase 1 study (NCT04139434) evaluating as monotherapy (Arm 1) combination...